GlaxoSmithKline Australia Pty Ltd v Pharmacor Pty Ltd

Link copied
Case Copied 52 min read

FEDERAL COURT OF AUSTRALIA

GlaxoSmithKline Australia Pty Ltd v Pharmacor Pty Ltd [2014] FCA 1202

Citation: GlaxoSmithKline Australia Pty Ltd v Pharmacor Pty Ltd [2014] FCA 1202
Parties: GLAXOSMITHKLINE AUSTRALIA PTY LTD v PHARMACOR PTY LTD
File number: VID 649 of 2014
Judge: BEACH J
Date of judgment: 12 November 2014
Catchwords: PRACTICE AND PROCEDURE — application for preliminary discovery — r 7.23 of the Federal Court Rules 2011 (Cth) — paracetamol products — potential right to relief arising from respondent’s alleged contravention of ss 18 and 29 of the Australian Consumer Law and/or infringement of patent — applicant seeking discovery and inspection of inter alia documents lodged with the Therapeutic Goods Administration (TGA) — applicant seeking order for provision of samples pursuant to s 23 of the Federal Court of Australia Act 1976 (Cth) — reasonableness of belief — representations made by respondent — whether respondent’s products are bioequivalent to applicant’s products — TGA approval of products as bioequivalent — meaning of bioequivalent — potentially misleading or deceptive conduct or false representations by respondent to pharmacists and consumers — whether reasonable inquiries made by applicant — respondent’s control of material —order for preliminary discovery made
Legislation: Competition and Consumer Act 2010 (Cth), Sch 2 (Australian Consumer Law) ss 18, 29(1)(a) and (1)(g)
Federal Court of Australia Act 1976 (Cth) s 23
Federal Court Rules 2011 (Cth) r 7.23
Cases cited: Apache Northwest Pty Ltd v Newcrest Mining Ltd (2009) 182 FCR 124
AstraZeneca AB v Alphapharm Pty Ltd [2014] FCA 9
Australian Competition and Consumer Commission v TPG Internet Pty Ltd (2013) 250 CLR 640
Benchmark Certification Pty Ltd v Standards Australia International Ltd (2004) 212 ALR 464
Brown v Riverstone Meat Co Pty Ltd (1985) 60 ALR 595
Butcher v Lachlan Elder Realty Pty Ltd (2004) 218 CLR 592
Concrete Constructions (NSW) Pty Ltd v Nelson (1990) 169 CLR 594
Demagogue Pty Ltd v Ramensky (1992) 39 FCR 31
Forrest v Australian Securities and Investments Commission (2012) 247 CLR 486
Glueck v Stang (2008) 76 IPR 75
Gold & Copper Resources Pty Ltd v Newcrest Operations Ltd [2013] NSWSC 281
Google Inc v Australian Competition and Consumer Commission (2013) 249 CLR 435
Interpharma Pty Ltd v Commissioner of Patents (2008) 107 ALD 342
Miller and Associates Insurance Broking Pty Ltd v BMW Australia Finance Ltd (2010) 241 CLR 357
ObjectiVision Pty Ltd v Visionsearch Pty Ltd [2014] FCA 1087
Optiver Australia Pty Ltd v Tibra Trading Pty Ltd (2008) 169 FCR 435
Reeve v Aqualast Pty Ltd [2012] FCA 679
Specsavers Pty Ltd v Canstar Blue Pty Ltd [2010] FCA 1153
St George Bank Ltd v Rabo Australia Ltd (2004) 211 ALR 147
Stratford Sun Ltd v OM Holdings Ltd (2009) 74 ACSR 698
Village Building Co Ltd v Canberra International Airport Pty Ltd (2004) 139 FCR 330
Date of hearing: 5 and 7 November 2014
Place: Melbourne
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 128
Counsel for the Applicant: Mr D Shavin QC with Ms H…
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read GlaxoSmithKline Australia Pty Ltd v Pharmacor Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] FCA 1202
Decision Date

CaseChat Overview and Summary

GlaxoSmithKline Australia Pty Ltd (GSK) sought an order for preliminary discovery from Pharmacor Pty Ltd, the respondent, in a case before the Federal Court of Australia. GSK, the applicant, sought discovery and inspection of documents lodged with the Therapeutic Goods Administration (TGA) and samples of the respondent's products. The dispute concerned potential rights to relief arising from the respondent's alleged contravention of the Australian Consumer Law and/or infringement of a patent. GSK sought the order under rule 7.23 of the Federal Court Rules 2011 (Cth) in relation to claims of misleading or deceptive conduct concerning the proposed promotion and supply of the respondent's products.

The court considered whether the applicant had satisfied the conditions in rule 7.23(1)(a) to justify the preliminary discovery. The court noted the inherent uncertainty in these preconditions, but did not see a basis to refuse relief based on a general assessment of uncertainty. The court examined the reasonableness of GSK's belief that the respondent's products were not bioequivalent to GSK's products, and whether the respondent had made potentially misleading or deceptive conduct or false representations to pharmacists and consumers. The court also considered whether GSK had made reasonable inquiries and whether the respondent controlled the material.

The court found that GSK was entitled to an order for preliminary discovery in relation to the ACL claims concerning the half-truth scenario or misleading or deceptive conduct. The court directed the parties to confer on the precise form of the preliminary discovery orders and stood the application over until 9.30 am on 13 November 2014. Costs were reserved. The entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Orders

Orders of the court

1. The parties are to confer forthwith as to the precise form of the preliminary discovery orders to be made to accord with my reasons published today.

2. The application be stood over until 9.30 am on 13 November 2014.

3. Costs reserved.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

In my view, uncertainty is inherent in the preconditions to be established under r 7.23(1)(a) in order to justify preliminary discovery. If such a precondition has been satisfied, I accept that I have a discretion to refuse relief nevertheless. But I do not see a proper basis to refuse preliminary discovery in this case based upon some more general assessment of uncertainty in terms of the elements of r 7.23(1)(a). CONCLUSION In my view, GSK is entitled to an order for preliminary discovery in relation to the ACL claims dealing with the half-truth scenario or misleading or deceptive conduct concerning the proposed promotion and supply of the Pharmacor Products to pharmacists or consumers. I will discuss with counsel the form of orders to be made.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.